About Affymetrix

Stock Quote

Security
AFFX (Common Stock)
$9.65
+0.10%
Current Day's High
9.90
Current Day's Low
9.61
Current Day's Volume
3,280,093
Last Trade
Dec 19 14 4:00 p.m. ET
Exchange
NASDAQ GS

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Bookmark and Share

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Affymetrix Applauds Congress and President for Enacting the Genetic Information Nondiscrimination Act

Company Plays Leading Role in Helping to Prevent the Misuse or Abuse of Genetic Information

SANTA CLARA, Calif.--(BUSINESS WIRE)--May 21, 2008--Affymetrix Inc. (Nasdaq:AFFX) applauds the U.S. Congress and President George W. Bush for enacting the Genetic Information Nondiscrimination Act (GINA). GINA establishes a much-needed federal prohibition in the United States against genetic discrimination and enacts a national standard for ensuring the privacy of personal genetic information. For more than seven years, Affymetrix has been recognized as a leading industry voice in helping to support and promote this important civil rights legislation.

Affymetrix products enable scientists to turn genetic information into specialized detailed knowledge. Since its inception, the company has helped to prevent the misuse or abuse of this knowledge through a number of grassroots efforts, educational programs and public policy initiatives. Affymetrix co-founded and has been an active executive committee member of the Coalition for Genetic Fairness, an influential organization established to promote genetic nondiscrimination policy. The company also offers a number of educational resources for teachers and students interested in learning more about genes and ethics.

"Affymetrix would like to thank President Bush and members of Congress for transforming GINA into a U.S. law. We have actively supported this much-needed legislation for more than seven years and we are pleased to see the U.S. government take steps toward addressing the issues around genetic discrimination," said Stephen P.A. Fodor, Ph.D., founder, chairman and CEO of Affymetrix. "Affymetrix is engaged in many efforts to encourage the appropriate use of genetic information and to ensure that people around the world continue to benefit from the latest scientific and technological advances. A better understanding of our genome will lead to improved healthcare and an enhanced quality of life."

To learn more about the Coalition for Genetic Fairness, please visit: www.geneticfairness.org.

About Affymetrix

Affymetrix GeneChip(R) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 12,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties related to the implications of the Genetic Information Nondiscrimination Act (GINA) law discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip(R) are registered trademarks owned or used by Affymetrix Inc.

CONTACT: Affymetrix Inc.
Media:
Andrew Noble, 408-731-5571
Associate Director, Corporate Communications
or
Investor:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
SOURCE: Affymetrix Inc.



Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.


Back to Top >